Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Credit agrmnt [a]
Appointed director
Kadmon Holdings, Inc. (KDMN) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/04/2021 8-K Quarterly results
Docs: "REZUROCK™ · On August 19, 2021 REZUROCK became commercially available for shipment to prescribed patients in the United States through a network of rare hematology/oncology specialty pharmacies and distributors o Execution of commercial launch remain underway, with a focus on generating awareness of REZUROCK's differentiated clinical value and facilitating market access o Experienced field team call on all target accounts, including engagement with 100% of the top 80 transplant centers, where ~90% of chronic graft-versus-host disease patients in the U.S. are treated o Strong sales performance and demand during initial launch period; $12.2 million net sales achieved in 3Q 2021 o The Company plans to present data on belumosudil at the 63rd American Society of Hematology Annual Me..."
08/05/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "About Belumosudil Belumosudil is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 , a signaling pathway that modulates inflammatory response and pro-fibrotic processes. The Company has submitted an NDA for belumosudil for the treatment of patients with cGVHD and the NDA is being reviewed under the FDA’s RTOR pilot program. The FDA has granted Breakthrough Therapy Designation to belumosudil for the treatment of patients with cGVHD after failure of two or more lines of systemic therapy. The FDA has also granted Orphan Drug Designation to belumosudil for the treatment of cGVHD. In addition, belumosudil is in Phase 2 clinical development in patients with diffuse cutaneous systemic sclerosis . The FDA has granted Orphan Drug Designation to belumosudil for the treatment of syste..."
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Kadmon Provides Business Update and Reports Third Quarter 2019 Financial Results NEW YORK, November 7, 2019 – Kadmon Holdings, Inc. today provided a business update and reported financial and operational results for the third quarter of 2019."
08/05/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "Recent Business Highlights Kadmon strengthened its leadership team with the naming of three new members of the Board of Directors and the addition of a key executive: · David E. Cohen, M.D., MPH, was appointed to the Board of Directors in February 2019. Dr. Cohen is the Charles C. and Dorothea E. Harris Professor of Dermatology at New York University School of Medicine, where he also serves as Chief of Allergy and Contact Dermatitis, Vice Chairman of Clinical Affairs, and Director of Occupational and Environmental Dermatology. · Arthur Kirsch has been nominated to stand for election to the Board of Directors at the 2019 Annual Meeting of Stockholders to be held on May 15, 2019. Mr. Kirsch has more than 40 years of experience leading global healthcare research and investment banki..."
11/09/2018 8-K Quarterly results
Docs: "Kadmon Provides Business Update and Reports Third Quarter 2018 Financial Results NEW YORK, November 9, 2018 – Kadmon Holdings, Inc. today provided a business update and reported financial and operational results for the third quarter of 2018."
05/08/2018 8-K Quarterly results
Docs: "Kadmon Provides Business Update and Reports First Quarter 2018 Financial Results NEW YORK, May 8, 2018 – Kadmon Holdings, Inc. today provided a business update and reported financial and operational results for the first quarter of 2018."
11/09/2017 8-K Quarterly results
Docs: "Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended , and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements may be preceded by the words “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, ..."
08/03/2017 8-K Quarterly results
Docs: "Kadmon Provides Business Update and Reports Second Quarter 2017 Financial Results NEW YORK, August 3, 2017 – Kadmon Holdings, Inc. today provided a business update and reported financial and operational results for the three and six months ended June 30, 2017."
05/15/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy